X
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
Other Certificates
Other Suppliers
USA (Orange Book)
Europe
Canada
Australia
South Africa
Uploaded Dossiers
U.S. Medicaid
Annual Reports
Details:
Icatibant injection, for subcutaneous is a bradykinin B2 receptor antagonist indicated for treatment of acute attacks of hereditary angioedema in adults 18 years of ageand older.
Lead Product(s): Icatibant Acetate
Therapeutic Area: Genetic Disease Product Name: Firazyr-Generic
Highest Development Status: ApprovedProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 16, 2023
Details:
SAJAZIR™ is a bradykinin B2 receptor antagonist indicated for treatment of acute attacks of hereditary angioedema (HAE) in adults 18 years of age and older.
Lead Product(s): Icatibant Acetate
Therapeutic Area: Genetic Disease Product Name: Sajazir
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 28, 2021
Details:
Icatibant, a complex injectable peptide product, forming part of high-value product, is an equivalent and more affordable version of Firazyr (Takeda/Shire), used used to treat a serious orphan disease, acute attacks of hereditary angioedema.
Lead Product(s): Icatibant Acetate
Therapeutic Area: Genetic Disease Product Name: Icatibant Acetate-Generic
Highest Development Status: ApprovedProduct Type: Peptide
Partner/Sponsor/Collaborator: AmbioPharm
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 28, 2021
Details:
This marks Glenmark's first synthetic decapeptide Icatibant Injection approval and will be manufactured in their North American manufacturing facility based in Monroe, North Carolina.
Lead Product(s): Icatibant Acetate
Therapeutic Area: Genetic Disease Product Name: Undisclosed
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 24, 2021
Details:
The latest development comes after the Data Monitoring Committee recommended concluding the icatibant arm on enrolling 95 patients and the agent meeting the predefined futility criterion.
Lead Product(s): Icatibant Acetate,Dexamethasone,Remdesivir
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 15, 2021
Details:
Sandoz in-licensed Icatibant injection, a critical anti-inflammatory medicine used to treat acute attacks of hereditary angioedema, from Slayback Pharma. Deal allows Sandoz to further grow its injectable medicine portfolio and supply another important medicine to US patients.
Lead Product(s): Icatibant Acetate
Therapeutic Area: Genetic Disease Product Name: Undisclosed
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Sandoz B2B
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement January 28, 2021
Details:
Icatibant injection is therapeutically equivalent to Firazyr®, and supplied as a 3 mL prefilled, single-use syringe that is self-administered subcutaneously into the abdominal area.
Lead Product(s): Icatibant Acetate
Therapeutic Area: Genetic Disease Product Name: Undisclosed
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 01, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
